Heat shock proteins as emerging therapeutic targets

被引:303
|
作者
Soti, C
Nagy, E
Giricz, Z
Vígh, L
Csermely, P [1 ]
Ferdinandy, P
机构
[1] Semmelweis Univ, Dept Med Chem, H-1085 Budapest, Hungary
[2] Inst Biochem, Biol Res Ctr, Szeged, Hungary
[3] Univ Szeged, Cardiovasc Res Grp, Dept Biochem, H-6720 Szeged, Hungary
关键词
chaperone coinducers; chaperones; Hsp90; Hsp70; heat shock proteins; geldanamycin; stress proteins; membrane fluidity;
D O I
10.1038/sj.bjp.0706396
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chaperones ( stress proteins) are essential proteins to help the formation and maintenance of the proper conformation of other proteins and to promote cell survival after a large variety of environmental stresses. Therefore, normal chaperone function is a key factor for endogenous stress adaptation of several tissues. However, altered chaperone function has been associated with the development of several diseases; therefore, modulators of chaperone activities became a new and emerging field of drug development. Inhibition of the 90 kDa heat shock protein ( Hsp) 90 recently emerged as a very promising tool to combat various forms of cancer. On the other hand, the induction of the 70 kDa Hsp70 has been proved to be an efficient help in the recovery from a large number of diseases, such as, for example, ischemic heart disease, diabetes and neurodegeneration. Development of membrane-interacting drugs to modify specific membrane domains, thereby modulating heat shock response, may be of considerable therapeutic benefit as well. In this review, we give an overview of the therapeutic approaches and list some of the key questions of drug development in this novel and promising therapeutic approach.
引用
收藏
页码:769 / 780
页数:12
相关论文
共 50 条
  • [1] Heat shock proteins as novel therapeutic targets in cancer
    Soo, Eliza T. L.
    Yip, George W. C.
    Lwin, Zin Mar
    Kumar, Srinivasan D.
    Bay, Boon-Huat
    IN VIVO, 2008, 22 (03): : 311 - 315
  • [2] HEAT SHOCK PROTEINS AS POTENTIAL THERAPEUTIC TARGETS IN ATHEROSCLEROSIS
    Madrigal-Matute, Julio
    Lopez-Franco, Oscar
    Blanco-Colio, Luis M.
    Munoz-Garcia, Begona
    Ramos-Mozo, Priscila
    van Oostrom, Melany
    Meilhac, Olivier
    Michel, Jean-Baptiste
    Egido, Jesus
    Martin Ventura, Jose L.
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2009, 21 (04): : 163 - 172
  • [3] Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets?
    Khalil, Ashraf A.
    Kabapy, Nihal F.
    Deraz, Sahar F.
    Smith, Christopher
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2011, 1816 (02): : 89 - 104
  • [4] Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
    Sajjad, M. U.
    Samson, B.
    Wyttenbach, A.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2010, 11 (02) : 198 - 215
  • [5] Exploring heat shock proteins as therapeutic targets for Parkinson's disease
    Li, Xiang
    Wang, Wenjun
    Pan, Shi
    Cao, Xueqin
    Thomas, Elizabeth Rosalind
    Xie, Mingyu
    Zhang, Chunxiang
    Wu, Jianming
    BIOCHEMICAL PHARMACOLOGY, 2024, 230
  • [6] Potential application of heat shock proteins as therapeutic targets in Parkinson?s disease
    Guo, Haodong
    Yi, Jingsong
    Wang, Fan
    Lei, Tong
    Du, Hongwu
    NEUROCHEMISTRY INTERNATIONAL, 2023, 162
  • [7] Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective
    Edkins, Adrienne L.
    Price, John T.
    Pockley, A. Graham
    Blatch, Gregory L.
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2018, 372 (1738)
  • [8] Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
    Zeng, L.
    Tan, J.
    Lu, T.
    Lei, Q.
    Chen, C.
    Hu, Z.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 38 - 46
  • [9] Heat shock proteins as targets in oncology
    Gimenez Ortiz, Alejandra
    Montalar Salcedo, Joaquin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (03): : 166 - 173
  • [10] Heat shock proteins as targets in oncology
    Alejandra Giménez Ortiz
    Joaquín Montalar Salcedo
    Clinical and Translational Oncology, 2010, 12 : 166 - 173